<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">568241</article-id><article-id pub-id-type="doi">10.26442/20751753.2023.4.202306</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Approach to the patient with adrenal incidentaloma. Case series</article-title><trans-title-group xml:lang="ru"><trans-title>Тактика ведения пациентов с инциденталомой надпочечников. Серия клинических случаев</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6418-7060</contrib-id><contrib-id contrib-id-type="spin">7958-9435</contrib-id><name-alternatives><name xml:lang="en"><surname>Ladygina</surname><given-names>Daria O.</given-names></name><name xml:lang="ru"><surname>Ладыгина</surname><given-names>Дарья Олеговна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. эндокринологии №1 Института клинической медицины им. Н.В. Склифосовского</p></bio><email>ladygina.do@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2234-5283</contrib-id><contrib-id contrib-id-type="spin">5670-4957</contrib-id><name-alternatives><name xml:lang="en"><surname>Zorina</surname><given-names>Anastasia A.</given-names></name><name xml:lang="ru"><surname>Зорина</surname><given-names>Анастасия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Clinical Resident</p></bio><bio xml:lang="ru"><p>клин. ординатор каф. эндокринологии №1 Института клинической медицины им. Н.В. Склифосовского</p></bio><email>azorina97@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4974-7765</contrib-id><contrib-id contrib-id-type="spin">4251-7117</contrib-id><name-alternatives><name xml:lang="en"><surname>Berkovskaya</surname><given-names>Marina A.</given-names></name><name xml:lang="ru"><surname>Берковская</surname><given-names>Марина Ароновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. эндокринологии №1 Института клинической медицины им. Н.В. Склифосовского</p></bio><email>abaitamar@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5592-4794</contrib-id><contrib-id contrib-id-type="spin">2459-0540</contrib-id><name-alternatives><name xml:lang="en"><surname>Chevais</surname><given-names>Anastassia</given-names></name><name xml:lang="ru"><surname>Шевэ</surname><given-names>Анастасия</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Endocrinologist</p></bio><bio xml:lang="ru"><p>врач-эндокринолог</p></bio><email>anastassia93@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7098-4584</contrib-id><contrib-id contrib-id-type="spin">4475-6327</contrib-id><name-alternatives><name xml:lang="en"><surname>Beltsevich</surname><given-names>Dmitry G.</given-names></name><name xml:lang="ru"><surname>Бельцевич</surname><given-names>Дмитрий Германович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотр.</p></bio><email>belts67@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2504-7468</contrib-id><contrib-id contrib-id-type="spin">6825-8417</contrib-id><name-alternatives><name xml:lang="en"><surname>Fadeev</surname><given-names>Valentin V.</given-names></name><name xml:lang="ru"><surname>Фадеев</surname><given-names>Валентин Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Corr. Memb. RAS</p></bio><bio xml:lang="ru"><p>чл.-кор. РАН, д-р мед. наук, проф., дир. клиники эндокринологии</p></bio><email>walfad@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center for Endocrinology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-04-10" publication-format="electronic"><day>10</day><month>04</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><issue-title xml:lang="en">Endocrinology</issue-title><issue-title xml:lang="ru">Эндокринология</issue-title><fpage>278</fpage><lpage>286</lpage><history><date date-type="received" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/568241">https://consilium.orscience.ru/2075-1753/article/view/568241</self-uri><abstract xml:lang="en"><p>The formations of the adrenal glands are often detected accidentally during instrumental methods of examination of the abdominal cavity and retroperitoneal space, performed for some other reasons. Over the past 2 decades, the frequency of detection of adrenal gland formations has increased 10-fold, and most of them are diagnosed in old age. The tactics of observation and treatment depend both on hormonal activity and on the malignant potential of the detected formation. Up to 5–8% of patients with adrenal incidentalomas have a malignant nature, with a higher risk in young patients, with a size of more than 4 cm, as well as with a history of other malignant neoplasms. The frequency of detection of the classical clinical and laboratory picture of hypercorticism, hyperaldosteronism or catecholamine-producing tumor is less than 15%, however, the phenomenon of functionally autonomous cortisol production according to the results of studies conducted in the last few years is much more common – up to 30–50% of patients. Despite the absence of vivid clinical symptoms in some cases, autonomous cortisol secretion is associated with increased cardiovascular morbidity and metabolic disorders, therefore, all patients with adrenal incidentalomas need to exclude this condition. This article presents clinical cases of patients with adrenal gland formations, describes in detail the examination algorithm and the choice of treatment tactics, taking into account the results of studies conducted since the release of the latest clinical recommendations for the management of patients with adrenal gland incidentalomas in 2016.</p></abstract><trans-abstract xml:lang="ru"><p>Образования надпочечников зачастую обнаруживаются случайно при проведении инструментальных методов обследования брюшной полости и забрюшинного пространства, выполняемых по каким-либо другим причинам. За последние 2 десятилетия частота выявления образований надпочечников увеличилась в 10 раз, причем большинство из них диагностируется в пожилом возрасте. Тактика наблюдения и лечения зависит как от гормональной активности, так и от злокачественного потенциала выявленного образования. До 5–8% пациентов с инциденталомами надпочечников имеют злокачественную их природу, при этом более высокий риск отмечен у молодых пациентов при размерах образования более 4 см, а также при наличии в анамнезе других злокачественных новообразований. Частота выявления классической клинической и лабораторной картины гиперкортицизма, гиперальдостеронизма или катехоламин-продуцирующей опухоли составляет менее 15%, однако феномен функционально автономной продукции кортизола по результатам исследований, проведенных в последние несколько лет, встречается значительно чаще – до 30–50% пациентов. Несмотря на отсутствие в ряде случаев яркой клинической симптоматики, автономная секреция кортизола связана с повышенной сердечно-сосудистой заболеваемостью и метаболическими нарушениями, поэтому всем пациентам с инциденталомами надпочечников требуется исключение данного состояния. В данной статье представлены клинические случаи пациентов с образованиями надпочечников, подробно описаны алгоритм обследования и выбор тактики лечения с учетом результатов исследований, проведенных с момента выхода последних клинических рекомендаций по ведению пациентов с инциденталомами надпочечников в 2016 г.</p></trans-abstract><kwd-group xml:lang="en"><kwd>incidentaloma</kwd><kwd>adrenal gland</kwd><kwd>pheochromocytoma</kwd><kwd>aldosteroma</kwd><kwd>adrenocortical cancer</kwd><kwd>Cushing's syndrome</kwd><kwd>subclinical hypercorticism</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>инциденталома</kwd><kwd>надпочечники</kwd><kwd>феохромоцитома</kwd><kwd>альдостерома</kwd><kwd>адренокортикальный рак</kwd><kwd>синдром Кушинга</kwd><kwd>субклинический гиперкортицизм</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Reimondo G, Castellano E, Grosso M, et al. Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study. J Clin Endocrinol Metab. 2020;105(4):e973-81.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ebbehoj A, Li D, Kaur RJ, et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(11):894-902.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171(2):107-16. DOI:10.7326/M18-3630</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-31. DOI:10.1210/jc.2015-1818</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Libè R, Dall’Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002;147(4):489-94. DOI:10.1530/eje.0.1470489</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020;67(2):141-52.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bancos I, Taylor AE, Chortis V, et al.; ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020;8(9):773-781.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Iniguez-Ariza NM, Kohlenberg JD, Delivanis DA, et al. Clinical, biochemical, and radiological characteristics of a single-center retrospective cohort of 705 large adrenal tumors. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):30-9.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hamidi O, Raman R, Lazik N, et al. Clinical course of adrenal myelolipoma: a long-term longitudinal follow-up study. Clin Endocrinol (Oxf). 2020;93(1):11-8.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab. 2019;104(5):1386-93.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. DOI:10.1210/jc.2014-1498</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mao JJ, Dages KN, Suresh M, Bancos I. Presentation, disease progression and outcomes of adrenal gland metastases. Clin Endocrinol (Oxf). 2020;93(5):546-54.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Delivanis DA, Erickson D, Atwell TD, et al. Procedural and clinical outcomes of percutaneous adrenal biopsy in a high-risk population for adrenal malignancy. Clin Endocrinol (Oxf). 2016;85(5):710-6.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sanford T, Gomella PT, Siddiqui R, et al. Long term outcomes for patients with von Hippel-Lindau and pheochromocytoma: defining the role of active surveillance. Urol Oncol. 2021;39(2):134.e1-8.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Corwin MT, Navarro SM, Malik DG, et al. Differences in growth rate on CT of adrenal adenomas and malignant adrenal nodules. AJR Am J Roentgenol. 2019;213(3):632-6.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pantalone KM, Gopan T, Remer EM, et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr Pract. 2010;16(4):577-87.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bouys L, Chiodini I, Arlt W, et al. Update on primary bilateral macronodular adrenal hyperplasia (PBMAH). Endocrine. 2021;71(3):595-603.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108-19.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Petr EJ, Else T. Adrenocortical carcinoma (ACC): when and why should we consider germline testing? Presse Med. 2018;47(7-8 Pt. 2):e119-25.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-34.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: updating the approach. J Cli Endocrinol Metab. 2020;105(12):3771-83.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Buitenwerf E, Berends AMA, van Asselt ADI, et al. Diagnostic accuracy of computed tomography to exclude pheochromocytoma: a systematic review, meta-analysis, and cost analysis. Mayo Clin Proc. 2019;94(10):2040-52.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ceccato F, Artusi C, Barbot M, et al. Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. J Endocrinol Invest. 2020;43(8):1105-13.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Vogg N, Kurlbaum M, Deutschbein T, et al. Method-specific cortisol and dexamethasone thresholds increase clinical specificity of the dexamethasone suppression test for Cushing syndrome. Clin Chem. 2021;67(7):998-1007.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526-40.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Giordano R, Marinazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010;162(4):779-85.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ueland GÅ, Grinde T, Methlie P, et al. Diagnostic testing of autonomous cortisol secretion in adrenal incidentalomas. Endocr Connect. 2020;9(10):963-70.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ceccato F, Barbot M, Albiger N, et al. Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. Endocrine. 2018;59(3):510-9.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Delivanis DA, Iñiguez-Ariza NM, Zeb MH, et al. Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas. Clin Endocrinol (Oxf). 2018;88(2):209-16.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>O’Shea PM, Griffin TP, Denieffe S, Fitzgibbon MC. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: promises and challenges. Int J Clin Pract. 2019;73(7):e13353. DOI:10.1111/ijcp.13353</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-48. DOI:10.1111/joim.12831</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Därr R, Kuhn M, Bode C, et al. Accuracy of recommended sampling and assay methods for the determination of plasmafree and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56(3):495-503.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Sbardella E, Grossman AB. Pheochromocytoma: An approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346. DOI:10.1016/j.beem.2019.101346</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Young WF, Bancos I. Adrenal disorders 100 cases from the adrenal clinic. Elsevier, 2022.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396-405.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Lopez D, Luque-Fernandez MA, Steele A, et al. “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med. 2016;165(8):533-42.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Di Dalmazi G, Vicennati V, Pizzi C, et al. Prevalence and incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: a long-term study. J Clin Endocrinol Metab. 2020;105(8):e2770-7.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Morelli V, Palmieri S, Lania A, et al. Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. Eur J Endocrinol. 2017;177(1):73-83.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Singh S, Atkinson EJ, Achenbach SJ, et al. Frailty in patients with mild autonomous cortisol secretion is higher than in patients with nonfunctioning adrenal tumors. J Clin Endocrinol Metab. 2020;105(9):e3307-15.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Kjellbom A, Lindgren O, Puvaneswaralingam S, et al. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas: a cohort study. Ann Intern Med. 2021;42(1):164-73.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Zhang CD, Li D, Kaur RJ, et al. Cardiometabolic outcomes and mortality in patients with adrenal adenomas: a populationbased cohort study. J Clin Endocrinol Metab. 2021;106(11):3320-30.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab. 2009;94(9):3207-14.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Chiodini I, Viti R, Coletti F, et al. Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin Endocrinol (Oxf). 2009;70(2):208-13.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Li D, Kaur RJ, Zhang CD, et al. Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study. Eur J Endocrinol. 2021;184(4):597-606.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Bancos I, Alahdab F, Crowley RK, et al. Therapy of endocrine disease: improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing’s syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(6):R283-95.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Salcuni AS, Morelli V, Eller Vainicher C, et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur J Endocrinol. 2016;174(3):261-9.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Dennedy MC, Annamalai AK, Prankerd-Smith O, et al. Low DHEAS: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. J Clin Endocrinol Metab. 2017;102(3):786-92.</mixed-citation></ref></ref-list></back></article>
